Lymphoma treatment guidelines
Disease | Date | Guideline |
DLBCL | APR 2018 | DLBCL guideline (Dutch only) |
21JUN2019 | DLBCL guideline - CONCEPT (Dutch only) | |
MCL | 11OCT2017 | MCL guideline (Dutch only) |
- | Please also find associated trials at the LLPC section | |
FL | 04FEB2020 | Folliculair Lymphoma guideline (Dutch only) |
HL | 13NOV2019 | Hodgkin Lymphoma guideline (Dutch only) |
MW | SEP 2012 | Morbus Waldenstrom guideline (Dutch only) |
Staging and response criteria
Please find the Staging and response criteria for lymphoma below
Lymphoma_Stadiering en respons criteria (Dutch only)
CZS Profylaxe
This guideline provides information on the CZS profylaxe
CZS profylaxe (Dutch only)
DLBCL treatment with Yescarta
As of May 1, 2020, Yescarta (axicabtagene ciloleucel) is included in the basic package for patients with relapsed / refractory DLBCL (including transformed LF and PMBCL) after at least 2 previous lines of systemic therapy. To make this treatment possible for all eligible patients, there is a central registration procedure and the indication is discussed in national consultation. More information about the application procedure and inclusion / exclusion criteria for treatment can be found in the following documents:
CD19 CAR T-cel update (06MAY2020)
In- en exclusiecriteria Yescarta buiten studieverband (04MAY2020)
Landelijk verwijsformulier CD19 CAR-T cel behandeling buiten studieverband (01MAY2020)